Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
AAA

Ratings ESG MSCI

Ratings Veracyte, Inc.: Strengths and Weaknesses

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Highlights: Veracyte, Inc.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Sales forecast by analysts have been recently revised upwards.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The group usually releases upbeat results with huge surprise rates.
Weaknesses: Veracyte, Inc.
  • With an expected P/E ratio at 37.14 and 31.09 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • The company's enterprise value to sales, at 3.75 times its current sales, is high.

Rating Financials

Veracyte, Inc. SectorUnited States

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

-

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

Long term EPS growth

-
More ratings

Rating Valuation

Veracyte, Inc. SectorUnited States

Global Valuation

Enterprise value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

-

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Veracyte, Inc. SectorUnited States

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Veracyte, Inc. SectorUnited States

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Veracyte, Inc. SectorUnited States

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
2.69B
AAA
2.25B - - - - -
2.23B
BBB
-
1.59B -
CCC
- -
1.1B -
AAA
- -
1.06B - - - - - - -
863M
CCC
703M - - - - - - -
496M
BB
-
472M - - - - - - -
Average 1.34B
BBB
Weighted average by Cap.
BBB
  1. Stock Market
  2. Equities
  3. VCYT Stock
  4. Ratings Veracyte, Inc.